In African-American patients with sickle cell disease (SCD), APOL1 G1 and G2 variants are associated with increased risk of sickle cell nephropathy (SCN). To determine the role of APOL1 variants in SCD patients living in Europe, we genotyped 152 SCD patients [aged 30Á4 (24Á3-36Á4) years], mainly of Sub-Saharan African ancestry, for APOL1 G1 and G2 and for variants of four genes with kidney tropism (GSTM1, GSTT1, GSTP1, and HMOX1). Homozygous or double-heterozygous APOL G1 and G2 genotypes were strongly associated with end stage renal disease (P = 0Á003) and worse Kidney Disease: Improving Global Outcomes stages (P = 0Á001). Further, these genotypes were associated in an age-dependent manner with lower estimated glomerular filtration rate (eGFR, P = 0Á008), proteinuria (P = 0Á009) and albuminuria (P < 0Á001) but not with other SCD complications. Compared to APOL1 G1/wild type (WT), the APOL1 G2/WT genotype was associated with a lower eGFR (P = 0Á04) in an age-dependent manner, suggesting that the G2/WT patients are likely to have worse kidney prognosis. Other genes variants analysed were not associated with SCN or other SCD complications. Our data indicate that APOL1 screening should be considered for the management of SCD patients, including those of non-African-American origin, as those with homozygous or double heterozygous variants are clearly at higher risk of SCN.
Chronic kidney disease (CKD) is a common complication of sickle cell nephropathy (SCN) and is associated with early mortality in sickle cell disease (SCD) (Platt et al, 1994; Powars et al, 2005; McClellan et al, 2012) . In childhood, SCN is mainly dominated by urine concentration disorders (Pham et al, 2000) , glomerular hyperfiltration (Hatch et al, 1970; Ware et al, 2010) and, sometimes, microalbuminuria (McKie et al, 2007; Marsenic et al, 2008) . In adulthood, microalbuminuria is more frequent (from 36% to 40%) (Haymann et al, 2010; Arlet et al, 2012; Drawz et al, 2016) and may progress to macroalbuminuria. This phenomenon is associated with a progressive decline in glomerular filtration rate (GFR), which can lead to end-stage renal disease (ESRD) (Ataga et al, 2014) .
Not all patients with SCD ultimately develop CKD (Powars et al, 2005) . Age is the most constant factor associated with CKD in SCD patients. Other factors associated with CKD are pre-hypertensive blood pressure profiles (Becker et al, 2014) , increased blood pressure (Thompson et al, 2007) , the HBB S (b S gene) haplotypes (Powars et al, 1991) , pulmonary hypertension (Ataga et al, 2010) , stroke (Wigfall et al, 2000) , low haemoglobin levels (Faulkner et al, 1995; Asnani et al, 2016) , haemolysis (Gurkan et al, 2010; Day et al, 2012; Ranque et al, 2014) , and haemoglobinuria (Saraf et al, 2014) . However, these factors (particularly haemolysis) are not associated with CKD in all cohorts (Guasch et al, 2006; Ataga et al, 2010; Asnani et al, 2011) , reflecting the complexity of SCN pathophysiology. Genotype-phenotype studies have identified several associations between gene polymorphisms and the risk of SCN in the African-American population (Nolan et al, 2007; Ashley-Koch et al, 2011; Saraf et al, 2015 Saraf et al, , 2017 Schaefer et al, 2016) . The G1 and G2 variants of apolipoprotein L-1 (APOL1), either homozygous (G1/G1 or G2/G2) or double heterozygous (G1/ G2), were associated with proteinuria (measured by urine dipstick) and a lower estimated glomerular fraction rate (eGFR) in one study (Ashley-Koch et al, 2011) , and with albuminuria, proteinuria, haemoglobinuria and a lower eGFR in two other studies performed by the same investigators in adults patients (Saraf et al, 2015 (Saraf et al, , 2017 . Moreover, the G1 variant of APOL1 (homozygous G1/G1) was recently found to be associated with albuminuria in children with SCD (Schaefer et al, 2016) .
The G1 allele of APOL1 has two missense variants (S342G and I384M), and the G2 allele has a deletion of six base pairs (Genovese et al, 2010; Tzur et al, 2010) . These two derived variants of APOL1 probably rose to higher allele frequency in certain regions of Sub-Saharan Africa under the evolutionary selective pressure which provided an extended spectrum resistance to virulent strength of Trypanosoma Brucei, including rhodesiense, gambiense and, possibly, other pathogens (Genovese et al, 2010; Tzur et al, 2010 ). An evolutionist parallel can be drawn with the S variant of HBB (responsible for SCD) as a factor of resistance to malaria (Bunn, 2013) . Inheriting two APOL1 risk variants (either homozygous or compound heterozygous) is associated with kidney diseases, such as nephroangiosclerosis and focal segmental glomerulosclerosis (FSGS) (Genovese et al, 2010; Tzur et al, 2010; Klotman et al, 2013) , human immunodeficiency virus associated nephropathy (HIVAN) (Kopp et al, 2011; Papeta et al, 2011) and severe lupus nephritis (Larsen et al, 2013; , in the African American population. These APOL1 risk variants work as a second hit that promotes the progression of kidney disease only in specific chronic kidney injury (Freedman & Skorecki, 2014) . These studies have led to the homozygous or compound heterozygous of G1 and G2 haplotypes being classified as high-risk variants. A variant of haem-oxygenase type 1 (HMOX1) (rs743811) has also been associated with CKD/ ESRD in SCD in the African-American population (Saraf et al, 2015) . Recently, the glutathione S-transferase-mu 1 (GSTM1) null variant was associated with faster progression of chronic renal failure secondary to hypertension, with a combining deleterious effect of APOL1 risk variants in the African-American population (Bodonyi-Kovacs et al, 2016) .
Of note, all studies on APOL1 variants in SCD have been conducted in African-American populations. Numerous studies have reported a wide haplotype distribution of the gene resulting in SCD (HBB) among world SCD populations (Bitoungui et al, 2015) , which is consistent with known historical migrations of the people from Africa to America. Our European population of SCD patients essentially comes from a recent migration from various African countries, which are expected to be different from Afro-American SCD patients who are essentially descendants of the slave trade, restricted to some West African countries.
Moreover, potential associations between APOL1, HMOX1 or GSTM1 variants and the other acute and chronic extrarenal manifestations of SCD have not been studied in detail. The chronic complications of SCD share common pathophysiological mechanisms with SCN (vasculopathy, capillary flow reduction, micro-thrombosis, ischaemia, toxicity of haem and free haemoglobin). Therefore, some gene variants favouring the occurrence of SCN may also play detrimental roles in other organs affected by the disease.
In this study, we first aimed to examine the association of G1 and G2 variants of APOL1 and of HMOX1, GSTM1, GSTP1 and GSTT1 variants with the occurrence of SCD complications, including SCN, in a cohort of SCD patients living in France. These patients differ genetically from the previously studied African-American population.
Our secondary objective was to study the potential differential effect of G1 and G2 variants of APOL1 on SCN pathology.
Patients and methods

Patients
Between March 2012 and March 2016, we prospectively enrolled adult (aged >18 years) SCD patients receiving routine medical care at European Georges Pompidou Hospital (EGPH) or Necker Hospital, Paris, France. All the included patients provided written informed consent for DNA analysis of genes likely to modify the course of SCN. The study was approved by the institutional review boards of the participating institutions (IRB registration #: 00001072). For the analyses, SCD patients were grouped into three genotypes: HbSS and Sb 0 ; SC; and Sb + and other rare SCD genotypes. The geographical origin of APOL1 alleles was defined as the country of birth of the parents. Clinical and laboratory data were retrospectively extracted from the electronic medical record charting system at routine follow-up outpatient visits during steady state of disease for at least 1 month (no acute illness, no vaso-occlusive or acute chest syndrome episode). One visit per year was recorded, when available. Behavioural activity, cardiovascular risk factors and the status of hepatitis C virus (HCV) infection, hepatitis B virus (HBV) or human immunodeficiency virus (HIV) were recorded at each visit.
The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (Levey et al, 2009 ) without correcting for ethnicity, the best method to estimate GFR in SCD (Arlet et al, 2012) . Based on the worst recorded eGFR of each patient during follow-up, we divided the patients into six stages of CKD (stage 1, 2, 3a, 3b, 4, 5) according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (National Kidney Foundation, 2002) .
Urinary collections were performed using the second void. Urine protein and albumin concentrations were determined from baseline and subsequent visits and the ratios for proteinuria/creatininuria and albuminuria/creatininuria were calculated and expressed in g/mmol or mg/mmol, respectively. Microalbuminuria and macroalbuminuria were defined as ratios of albuminuria/creatininuria >3 mg/mmol and >30 mg/mmol, respectively. Proteinuria was defined as a ratio of proteinuria/ creatininuria >0Á03 g/mmol, and glomerular proteinuria as a ratio of albuminuria/proteinuria ratio >60%.
Extra-renal acute complications that resulted in hospitalization for acute sickle cell crisis, hospitalization for acute chest syndrome, history of priapism for men, stroke (ischaemic or haemorrhagic), and/or known cerebral vasculopathy (Moya-Moya, aneurysm, arterial stenosis), vein thrombosis and/or pulmonary embolism were noted. Acute sickle cell crisis was classified as follows: no crisis, 1-2 crises, ≥3 crises per year (assessed by the mean annual number of vaso-occlusive crises requiring emergency admission within the last 5 years).
Extra-renal chronic complications involved history of osteonecrosis, sickle-cell ophtalmopathy, secondary haemochromatosis (and/or treatment by iron chelators), leg ulcer, chronic pulmonary hypertension and cardiopathy.
Transthoracic echocardiography was performed at least once in 123 of 152 patients during follow-up. Chronic pulmonary hypertension was screened by Doppler ultrasound; of note, a peak tricuspid regurgitation jet velocity equal to or greater than 2Á5 m/s was found to be associated with an increased risk for mortality in SCD but does not always refer to real pulmonary hypertension. Indeed, right heart catheterization is the gold standard examination, but is rarely performed in SCD patients in clinical practice (Klings et al, 2014) . The definition of cardiopathy was based on that reported by Damy et al (2016) for men. Cardiac dysfunction was defined as left ventricular ejection fraction <55%. Splenectomy, cholecystectomy and other treatments, such as angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), hydroxycarbamide and the age of beginning of these treatments were also recorded. At each visit, haemoglobin level, mean corpuscular volume, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), total bilirubin, reticulocytes count were recorded. Haemoglobin level, mean corpuscular volume, LDH, AST, total bilirubin, and reticulocyte count values after the introduction of hydroxycarbamide were removed from the analysis, because of the strong impact of this drug on these parameters.
DNA extraction and genotyping analysis
Patients were genotyped for seven polymorphisms in five genes at EGPH, Paris. Genomic DNA was extracted from peripheral blood leucocytes using the Maxwell â 16 LEV Blood DNA Kit (Promega, Charbonni eres-les-Bains, France) according to the recommendations of the manufacturer. APOL1 G1 haplotype (rs73885319, and rs60910145) and APOL1 G2 haplotype (rs71785313) were identified by sequencing. The APOL1 allele consisting of rs73885319 APOL1 G1 and G2 Variants in SCD: Kidney is the Main Target ª 2017 John Wiley & Sons Ltd without rs60910145 was designated as G1a, and considered as a wild-type (WT) allele. Sequencing was performed on an ABI Prism Genetic Analyser System 9700 (Applied Biosystems, Thermo Fisher Scientific, Courtaboeuf, France). The GSTM1, GSTT1 and GSTP1 genotypes were determined as previously described (Lecomte et al, 2006) . Polymerase chain reaction (PCR) was used to detect deletions in GSTT1 and GSTM1, and PCR-restriction fragment length polymorphism was used to detect the GSTP1 polymorphism. Primers and cycling conditions are listed in Table SI . The HMOX1 SNP (rs743811) was identified using TaqMan â Genotyping Assay (C___8956192_10). Genotypes were distributed according to the Hardy Weinberg Equilibrium (Table SII) . We then assessed the association between each of the genotyped variants and both renal and extra-renal patient characteristics using a Fisher exact test for qualitative variables and an analysis of variance F-test for quantitative variables. Tests for APOL1 and GSTP1 compared the three groups: homozygous or double heterozygous versus heterozygous versus WT. For the HMOX1 variant, only one patient was homozygous and was therefore pooled with heterozygotes. A recessive model was considered for GSTT1 and GSTM1 variants; the tests compared two groups: WT and heterozygotes versus homozygotes.
Statistical analysis
To take into account multiple testing, the threshold of significance was taken as 0Á5% (P = 0Á005).
We then assessed whether the highlighted association between APOL1 variants with SCN persisted after adjustment and whether it was age-dependent. We tested the association between APOL1 variants and eGFR, proteinuria/creatininuria and albuminuria/creatininuria using a linear mixed model with SCD genotype, treatment with ACEI, ARB, or hydroxycarbamide, and age as fixed effects and individuals as random effects. For the linear mixed model analysis, all available ratios (of proteinuria and albuminuria) and all values of eGFR were used for the analysis.
Because the risks of SCN associated with APOL1 G1 and G2 might be different, we also performed a sub-group analysis comparing renal characteristics among patients with G1/ WT and G2/WT variants using a Fisher exact test for qualitative variables and an analysis of variance for quantitative variables, and we applied the linear mixed model to compare G1/WT and G2/WT. The threshold of significance was taken as 5% for this sub-group analysis, because we only explored the association of these variants with only few variables that were all related to renal function.
All analyses were performed using R version 3.0.2 and the nlme package (both R Foundation for Statistical Computing, Vienna, Austria) for mixed model analysis.
Results
Population description
The clinical characteristics of the 152 SCD patients are summarized in Table I . As expected, compared to other genotypes, the SS/Sb 0 patients had higher numbers of past acute chest syndrome and cholecystectomy events, lower haemoglobin, higher mean corpuscular volumes and markers of haemolysis, secondary hemochromatosis, left ventricular mass, and were more often treated with hydroxycarbamide. The SC patients had a higher risk of retinopathy compared to other genotypes. The patients with macroalbuminuria were significantly older, more often hypertensive, and suffered more from left cardiac hypertrophy, higher tricuspid regurgitation jet velocity and chronic kidney failure (Table SIII) . Of note, none of the studied variants or SCD genotypes was associated with macroalbuminuria in this cross-sectional analysis.
Effects of APOL1, HMOX1, GSTM1, GSTT1 and GSTP1 variants on acute and chronic organ involvement of SCD including SCN
The clinical characteristics of the cohort according to APOL1 polymorphisms are summarized in Table II , and the geographic origin of the APOL1 alleles are shown in Fig 1. APOL1 genotypes were not associated with ethnicity (comparison of Sub-Saharan versus West Indies only; data not shown). Ten (8 SS, 2 SC) of the 152 patients (7%) were homozygous or double heterozygous (G1/G1, n = 3; G2/G2, n = 1; G1/G2, n = 6), and 52 patients (34%) were heterozygous for APOL1 variants (G1/WT or G2/WT).
After correction for multiple testing, ESRD and KDIGO stages were the only variables significantly associated with homozygous or double heterozygous polymorphisms of APOL1. Thus, 30% of patients with APOL1 high risk variants presented ESRD versus only 1% for the WT patients [OR = 32Á3 (3Á31; 1005Á7)]. Albuminuria was not associated with APOL1 polymorphisms in this cross-sectional analysis. Interestingly, all (5/5) of the patients with APOL1 homozygous or double heterozygous variants had a glomerular proteinuria, whereas this was found in 60% (9/15) of heterozygous and only 32% (9/28) of WT patients (P = 0Á01). There was a trend for increased annual median We then tested whether the association between APOL1 variants and SCN persisted when adjusting for potential confounding factors. We performed a linear mixed model analysis taking into account SCD genotype, treatments with ACEI, ARB or hydroxycarbamide, and age (Fig 2) . APOL1 high-risk variants were associated with significantly worse albuminuria (P < 0Á001) in an age-dependent manner. No difference was detected between WT and heterozygous APOL1 variants (Fig 2A) . Findings for proteinuria and eGFR were similar: a worse proteinuria and eGFR were detected for high-risk variants versus the WT genotype (P = 0Á009 and P = 0Á008), and no significant difference between WT and heterozygous variants was detected (Fig 2B, C) . This analysis confirmed the deleterious effect of homozygous or double heterozygous polymorphisms of APOL1 on kidney function and highlighted the association between these variants and the early onset of renal disease.
Differential roles of APOL1 G1 and G2 variants
Given the recent mechanistic findings in the zebrafish (Anderson et al, 2015) , we tested the hypothesis that the G1 and G2 alleles do not result in the same risk for SCN. We performed an analysis in the sub-group of heterozygotes, which comprised 52 patients: 32 G1/WT and 20 G2/WT patients. Frequencies of KDIGO stages >1 were different between G1/WT and G2/WT (respectively 1/32 vs. 5/20, P = 0Á026), but frequencies of ESRD (0/32 vs. 3/20, respectively, P = 0Á052) and albuminuria did not differ by haplotype.
In the linear mixed model analysis adjusted for age and for treatments with ACEI, ARB or hydroxycarbamide, we found that compared to APOL1 G1/WT group, the APOL1 G2/WT group was associated with a lower eGFR in an age-dependent manner (P = 0Á045) ( Figure S1 ). There was no difference for albuminuria (P = 0Á199) or proteinuria (P = 0Á071).
Discussion
This study confirmed a strong association of homozygous and double-heterozygous polymorphisms of both G1 and G2 APOL1 variants with SCN in our SCD patients. The patients in our cohort were predominantly of sub-Saharan African origin (73%). To our knowledge, this is the first study of prevalence of these variants in a population primarily of African origin. Prevalence of the homozygosity and compound heterozygosity for APOL1 G1/G2 in our cohort (7%) was approximately half of that reported in previous studies in SCD patients with African-American origin [14% (Saraf et al, 2015) and 12Á3% (Saraf et al, 2017) ].
Cross-sectional analysis of our patient cohort showed that APOL1 G1 and G2 variants were associated with an approximately 30-fold higher risk of ESRD and worse KDIGO stages. Moreover, a specific kidney tropism of APOL1 variants was evidenced, because APOL1 variants did not correlate with non-kidney associated SCD complications in our study. Freedman and Skorecki (2014) previously demonstrated that APOL1 risk variants were more strongly associated with ESRD than with more moderate kidney disease, suggesting a more pronounced role in nephropathy progression to endstage rather than initiation of CKD. We also demonstrated, for the first time, an earlier onset of SCN in SCD patients with APOL1 risk variants. Of note, a 3-fold increased risk for early mortality was previously observed in SCD patients with CKD (Darbari et al, 2013) . Thus, the role of APOL1 risk variants on earlier mortality because of CKD in SCD patients should be determined in the future in longer prospective cohorts. We did not confirm the association of HMOX1 rs743811 variant with SCN, as recently described (Saraf et al, 2015) , but our cohort was mainly composed of WT and heterozygous individuals (and only one homozygous for the rs743811 variant). We did not find any association of GSTM1, GSTP1 or GSTT1 null variants with SCD manifestations including SCN.
APOL1 expression in the kidney has been studied (Madhavan et al, 2011; Ma et al, 2015) . APOL1 is expressed in several kidney cell types including podocytes, proximal tubular epithelial cells and the arterial endothelium. In FSGS and HIVAN, the podocyte expression of APOL1 is decreased, and there is de novo expression of APOL1 in the medium-sized arteries and arterioles. Nevertheless, no difference in protein expression was observed in physiological and diseased conditions in patients with variants of APOL1 compared to wildtype alleles (Madhavan et al, 2011) . Shorter renal allograft survival is observed in kidney transplants from donors with APOL1 variants (Reeves-Daniel et al, 2011) . Moreover, plasma levels of G1 or G2 APOL1 are not associated with renal disease (Kozlitina et al, 2016) . Recently, APOL1 risk variants have been shown to cause cytotoxicity in human embryonic kidney cells by depleting cellular potassium and inducing stress-activated protein kinases (Olabisi et al, 2016) . Impaired mitochondrial function was also demonstrated in HEK293 cell lines stably expressing doxycycline-inducible (Tet-on) G1 and G2 renal-risk variants (Ma et al, 2017) . Taken together, all these results indicate that APOL1 risk variants play specific intra-renal deleterious roles and probably explain why we did not find any association between APOL1 variants and extra-renal acute or chronic manifestations of SCD.
The inhibition of APOL1 expression in zebrafish results in loss of nephrin expression, leading to a severe dysfunction of the glomerular filtration barrier, which could be rescued by expression of the human nephrin (NPHS1) mRNA (Kotb et al, 2016) . Complementation of morphants lacking the APOL1 gene with WT human APOL1 mRNA also rescues the glomerular filtration barrier defect (Anderson et al, 2015) . However, the APOL1 G1 or G2 risk alleles do not ameliorate defects caused by APOL1 suppression (Anderson et al, 2015) . These results suggest the hypothesis that, in the context of decreased expression of APOL1 in the podocyte, APOL1 G1 and G2 proteins are not able to ensure efficient function of the podocyte, whereas WT APOL1 does. Interestingly, the proteinuria of SCD patients with homozygous or double heterozygous APOL1 variants in our study was always of glomerular origin. Although our population is small, this is also suggestive of dysfunction in the glomerular filtration barrier due to certain APOL1 variants.
In zebrafish, APOL1 G2, but not G1, expression alone promotes developmental kidney defects, suggesting a possible dominant-negative effect of the altered protein (Anderson et al, 2015) . For this reason, we performed a subgroup analysis and found that compared to G1/WT, APOL1 G2/WT polymorphism was significantly associated with a lower eGFR and a KDIGO stage >1. These results support the pathophysiological finding in zebrafish, given that we confirmed for the first time in humans that G2/WT is associated with a worse kidney prognosis than the G1/WT genotype. This effect may be specific to SCD, as a recent report found, contrary to our findings, that the effect size of G2 was weaker than G1 in HIVAN in Black South Africans (Kasembeli et al, 2015) .
An intravascular role of APOL1 variants in haemolytic diseases is also suspected (Saraf et al, 2015 (Saraf et al, , 2017 . APOL1 circulates in the blood bound to haptoglobin-related protein and to high density lipoprotein (Nielsen et al, 2006) . In SCD, as in other haemolytic diseases, the free haemoglobin that exceeds the capacity of binding to haptoglobin and to haptoglobin-related protein results in haemoglobinuria (Muller-Eberhard et al, 1968) . Free haemoglobin and haem are toxic to the glomeruli and kidney tubules in SCD patients (Fagoonee et al, 2005) . It was suggested that APOL1 variants may be less effective scavengers of free haemoglobin than WT APOL1 (Saraf et al, 2015 (Saraf et al, , 2017 . Indeed, the authors found an association between APOL1 variant genotypes and the level of haemoglobinuria in SCD patients (Saraf et al, 2015 (Saraf et al, , 2017 . We did not measure haemoglobinuria in our cohort, and we are therefore not able to confirm this result. APOL1 risk variants might play a double role in the progression of CKD in SCD patients: a direct role inside glomerular cells (defective protection) and an indirect role by increasing toxicity of free haemoglobin and haem by less effective scavenging. The intravascular effects should also lead to an increased risk of leg ulcer, priapism, stroke and pulmonary hypertension (Tracz et al, 2007; Schaer & Buehler, 2013) ; this was not the case in our cohort, rendering the latter explanation less likely.
Our study has several limitations. The cross-sectional analysis is limited by the fact that each patient must be associated with a defined category of nephropathy, which may progress over time, and because we did not take into account age and treatments. The numbers of visits varied among patients, and proteinuria, albuminuria and other biological markers were not systematically measured at each visit. The long longitudinal follow-up did allow us to construct a valid linear mixed model analysis, which was better suited to detect the association of APOL1 risk variants with SCN than the cross-sectional analysis (i.e., albuminuria, proteinuria and eGFR). The sample size in our cohort was relatively small, especially for the homozygous and double heterozygous APOL1 groups. We had expected that more than 10% of patients would have an APOL1 mutation based on previous studies (Saraf et al, 2015 (Saraf et al, , 2017 , but our data suggest that the frequency of APOL1 risk variants is lower in those with SCD living in France who are primarily of African origin. For these reasons, we may have been underpowered to detect associations between APOL1 risk variants and extra-renal complications of SCD or biological abnormalities. Moreover, we cannot exclude a lack of statistical power that would fail to detect an association between HMOX1 variant (rs743811) and the GSTM1-null variant with kidney involvement. The association between G2/WT genotype and SCN will also need to be confirmed in larger prospective cohorts. The strength of this study relies on the exhaustive phenotype characterization of patients. In addition to already known classical associations, such as SCD genotype, age and hypertension with SCN, we observed associations between early onset of SCN with APOL1 risk variants and between the APOL1 G2/WT genotype with SCN, and the absence of association between APOL1 variants and extra-renal SCD acute or chronic complications. Moreover, this study is the first, to our best knowledge, performed in SCD patients from African-European origin.
Taken together, these data indicate that APOL1 polymorphism status should be determined for all SCD children in order to identify those high-risk patients who should be frequently screened for kidney involvement and would benefit from early nephroprotection. Because of the tremendous progress in the use of bone marrow allografts even in adult SCD patients, the only curative treatment to date, the APOL1 high risk variants could be one of the decision points for bone marrow transplant, and this should be undertaken before deterioration of kidney function.
In conclusion, we confirmed the strong association of APOL1 risk variants G1 and G2 with SCN in adult SCD patients but could not find any other association with other chronic complications of SCD. This study may have missed other relevant associations because of low sample size and unexpectedly low risk allele frequencies. We also demonstrated, for the first time in humans, that the APOL1 G2/WT variant is associated with a lower GFR than the APOL1 G1/ WT genotype. Screening for APOL1 variants should be considered for the management of SCD patients as early as possible in order to identify those high-risk patients who should be frequently screened for kidney involvement. 
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